Diamyd Medical AB (OSTO:DMYD B) Total Current Assets : kr340.18 Mil (As of May. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Diamyd Medical AB's total current assets for the quarter that ended in May. 2025 was kr340.18 Mil.

Diamyd Medical AB Total Current Assets Historical Data

The historical data trend for Diamyd Medical AB's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Total Current Assets Chart

Diamyd Medical AB Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Total Current Assets

Get a 7-Day Free Trial

72.39

162.97

173.01

140.81

159.14

Diamyd Medical AB Quarterly Data
	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25
Total Current Assets	Get a 7-Day Free Trial															183.44	159.14	163.85	123.24	340.18

Diamyd Medical AB Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Diamyd Medical AB's Total Current Assets for the fiscal year that ended in Aug. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	132.366	+	4.017	+	0	+	22.761
	=	159.14

Diamyd Medical AB's Total Current Assets for the quarter that ended in May. 2025 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	319.262	+	20.916	+	0	+	0.00099999999997635
	=	340.18

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Diamyd Medical AB (OSTO:DMYD B) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Diamyd Medical AB's Liquidation Value for the quarter that ended in May. 2025 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	319.262	-	75.398	+	0.75 * 0.041	+	0.5 * 0
=	243.89

Diamyd Medical AB Total Current Assets Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Diamyd Medical AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

DYMDF:USA

Address

Kungsgatan 29, Stockholm, SWE, SE-111 56

Website

https://www.diamyd.com

Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines